scholarly journals Metastatic progression of breast cancer: insights from 50 years of autopsies

2013 ◽  
Vol 232 (1) ◽  
pp. 23-31 ◽  
Author(s):  
Margaret C Cummings ◽  
Peter T Simpson ◽  
Lynne E Reid ◽  
Janani Jayanthan ◽  
Joanna Skerman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Progression

Characterisation of developmental pathways that drive metastatic progression of breast cancer at single cell resolution

2019 ◽  
Author(s):  
Fatima Valdes-Mora ◽  
Robert Salomon ◽  
Brian Gloss ◽  
Andrew MK Law ◽  
Kendelle Murphy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Single Cell ◽  
Developmental Pathways ◽  
Metastatic Progression

Breast Cancer-Secreted Laminin γ2 Promotes Metastatic Progression Through Attraction of Blood Vessels

2020 ◽  
Author(s):  
Lena Wullkopf ◽  
Louis E. Jensen ◽  
Edward R. Horton ◽  
Alejandro E. Mayorca Guiliani ◽  
Chris D. Madsen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Blood Vessels ◽  
Metastatic Progression

scholarly journals MiRNA10b-directed nanotherapy effectively targets brain metastases from breast cancer

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Byunghee Yoo ◽  
Alana Ross ◽  
Pamela Pantazopoulos ◽  
Zdravka Medarova
Keyword(s):  
Breast Cancer ◽  
Rna Interference ◽  
Lymph Nodes ◽  
Therapeutic Effect ◽  
Metastatic Breast ◽  
Treatment Modalities ◽  
Transcriptional Level ◽  
Metastatic Progression ◽  
Therapeutic Modalities ◽  
Metastatic Colonization

AbstractRNA interference represents one of the most appealing therapeutic modalities for cancer because of its potency, versatility, and modularity. Because the mechanism is catalytic and affects the expression of disease-causing antigens at the post-transcriptional level, only small amounts of therapeutic need to be delivered to the target in order to exert a robust therapeutic effect. RNA interference is also advantageous over other treatment modalities, such as monoclonal antibodies or small molecules, because it has a much broader array of druggable targets. Finally, the complementarity of the genetic code gives us the opportunity to design RNAi therapeutics using computational, rational approaches. Previously, we developed and tested an RNAi-targeted therapeutic, termed MN-anti-miR10b, which was designed to inhibit the critical driver of metastasis and metastatic colonization, miRNA-10b. We showed in animal models of metastatic breast cancer that MN-anti-miR10b accumulated into tumors and metastases in the lymph nodes, lungs, and bone, following simple intravenous injection. We also found that treatment incorporating MN-anti-miR10b was effective at inhibiting the emergence of metastases and could regress already established metastases in the lymph nodes, lungs, and bone. In the present study, we extend the application of MN-anti-miR10b to a model of breast cancer metastatic to the brain. We demonstrate delivery to the metastatic lesions and obtain evidence of a therapeutic effect manifested as inhibition of metastatic progression. This investigation represents an additional step towards translating similar RNAi-targeted therapeutics for the systemic treatment of metastatic disease.

scholarly journals LIMK2 promotes the metastatic progression of triple-negative breast cancer by activating SRPK1

Oncogenesis ◽  
2020 ◽  
Vol 9 (8) ◽  
Author(s):  
Parmanand Malvi ◽  
Radoslav Janostiak ◽  
Suresh Chava ◽  
Padmini Manrai ◽  
Esther Yoon ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Metastatic Progression

scholarly journals Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Katsutoshi Sato ◽  
Amol A. Padgaonkar ◽  
Stacey J. Baker ◽  
Stephen C. Cosenza ◽  
Olga Rechkoblit ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Kinase Inhibitor ◽  
Chemotherapy Resistance ◽  
Metastatic Progression ◽  
Resistant Disease ◽  
Risk Patients ◽  
Additional Support

AbstractTriple negative breast cancer (TNBC) remains challenging because of heterogeneous responses to chemotherapy. Incomplete response is associated with a greater risk of metastatic progression. Therefore, treatments that target chemotherapy-resistant TNBC and enhance chemosensitivity would improve outcomes for these high-risk patients. Breast cancer stem cell-like cells (BCSCs) have been proposed to represent a chemotherapy-resistant subpopulation responsible for tumor initiation, progression and metastases. Targeting this population could lead to improved TNBC disease control. Here, we describe a novel multi-kinase inhibitor, 108600, that targets the TNBC BCSC population. 108600 treatment suppresses growth, colony and mammosphere forming capacity of BCSCs and induces G2M arrest and apoptosis of TNBC cells. In vivo, 108600 treatment of mice bearing triple negative tumors results in the induction of apoptosis and overcomes chemotherapy resistance. Finally, treatment with 108600 and chemotherapy suppresses growth of pre-established TNBC metastases, providing additional support for the clinical translation of this agent to clinical trials.

The impact of loco-regional recurrences on metastatic progression in early-stage breast cancer: a multistate model

2009 ◽  
Vol 117 (2) ◽  
pp. 401-408 ◽  
Author(s):  
G. H. de Bock ◽  
H. Putter ◽  
J. Bonnema ◽  
J. A. van der Hage ◽  
H. Bartelink ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Metastatic Progression ◽  
Multistate Model ◽  
The Impact
Sign in / Sign up

Export Citation Format

Share Document